Constitutive activation of the ras proto-oncogene is a frequent and early event in colon cancers, but the downstream nuclear targets are not fully understood. The Cdx-1 and Cdx-2 homeobox genes play crucial roles in intestinal cell proliferation and dierentiation. In addition, Cdx-2 is a colonic tumour-suppressor gene, whereas Cdx-1 has oncogenic potential. Here, we show that constitutive activation of ras alters Cdx-1 and Cdx-2 expression in human colonic Caco-2 and HT-29 cells that harbour a normal ras proto-oncogene. Oncogenic ras downregulates Cdx-2 through activation of the PKC pathway and a decline in activity of the Cdx-2 promoter AP-1 site. This decline results from a PKC-dependent decrease in the relative expression of c-Jun, an activator of Cdx-2 transcription, compared to c-Fos, an inhibitor of Cdx-2. Unlike Cdx-2, Cdx-1 is upregulated by oncogenic ras and this eect is mediated by activation of the MEK1 pathway. These results indicate that oncogenic ras activation has opposite eects on Cdx-1 and Cdx-2 expression through distinct signalling pathways and they provide the ®rst evidence for a functional link between ras activation and the downregulation of the Cdx-2 tumour-suppressor gene in colon cancer cells.
Introduction
Tumour formation and progression involve multiple steps including loss of expression of tumour-suppressor genes and constitutive activation of proto-oncogenes (Fearon and Vogelstein, 1990; Ilyas and Tomlinson, 1996) . The intestinal-speci®c caudal-related Cdx-1 (Duprey et al., 1988; Freund et al., 1992; Hu et al., 1993) and Cdx-2 homeobox genes (James and Kazenwadel, 1991; James et al., 1994) encode nuclear transfactors that play critical roles in intestinal cell proliferation and dierentiation. Cdx-1 is mainly expressed in the crypt compartment although not restricted to proliferative cells (Silberg et al., 1997) , and its inhibition by antisense RNA reduces cell proliferation in vitro . The CDX-2 homeoprotein occurs mainly in the differentiating enterocytes (James et al., 1994) and it triggers growth retardation and cell dierentiation in several intestinal lines in vitro (Suh and Traber, 1996; Lorentz et al., 1997) . In addition, Cdx-1 and Cdx-2 are controlled by epithelial-mesenchymal cell interactions , via extracellular matrix components . Beside its role in cell dierentiation, Cdx-2 has recently been identi®ed as a new colonic tumour-suppressor gene, since heterozygous Cdx-2 knock-out mice develop multiple colonic adenomas in which cells fail to express the single resident gene (Chawengsaksophak et al., 1997) . Consistently, Cdx-2 expression drops in colon cancers in relation with the severity of displasia (Ee et al., 1995; Mallo et al., 1997) . On the contrary, Cdx-1 has oncogenic potential in vitro (Maulbecker and Gruss, 1993) . No colonic tumour has been reported in Cdx-1-de®cient mice (Subramaniam et al., 1995) and onset of Cdx-1 expression accompanies the development of intestinal metaplasia in the oesophagus and in the stomach (Silberg et al., 1997) . However, Cdx-1 downexpression has been observed in some colon cancers (Silberg et al., 1997; Mallo et al., 1997; Vider et al., 1997) .
Constitutive ras activation is an early and frequent event in colorectal cancers, but the downstream nuclear targets of oncogenic ras are not fully understood (Fearon and Vogelstein, 1990) . In human colonic Caco-2 cells, characterized by a spontaneous enterocytic-like dierentiation and with very low tumorigenic potential (Rousset et al., 1980; Pinto et al., 1983) , constitutive activation of ras results in higher tumorigenicity, as well as in altered cell growth and dierentiation Delage et al., 1993; Baron-Delage et al., 1996) . In particular, the expression of sucrase-isomaltase, a typical target of the CDX-2 homeoprotein (Suh et al., 1994) , is turned o (Baron- Delage et al., 1996) . This observation, together with the fact that Cdx-1 and Cdx-2 expression is altered in tumours of the digestive tract, prompted us to examine whether these homeobox genes are nuclear targets of oncogenic ras in colon cancer cells. For this purpose, Cdx-1 and Cdx-2 expression was investigated in Caco-2 cells in which ras was constitutively activated by stable transfection with either the mutated Val12 Ha-ras gene (Caco-2T cells), or with the cDNA encoding the polyoma middle T antigen (Caoco-2MT cells) Baron-Delage et al., 1994) . In these cells, the higher tumorigenic potential resulting from ras activation is associated with overexpression of PKC (Protein Kinase C) and constitutive activation of PKC and MAP kinases (Mitogen Activated Protein kinases) (Delage et al., 1993; Baron-Delage et al., 1994) .
Results
Opposite regulation of Cdx-1 and Cdx-2 by oncogenic ras in human colonic cancer cells
The endogenous levels of Cdx-1 and Cdx-2 mRNAs were compared in control Caco-2H cells and in the Caco-2T and Caco-2MT cell lines in which ras was constitutively activated by stable transfection with plasmids encoding the mutated Val12 Ha-ras oncoprotein or the polyoma middle T antigen. Figure 1a shows that constitutive ras activation was accompanied by an increase in Cdx-1 mRNA expression and inversely by a decrease in Cdx-2 mRNA level. Evidence for the involvement of ras in these modi®cations of homeobox gene expression was provided by transient transfection of Caco-2TC7 cells with the Val12 Haras-encoding plasmid pHO6T1. Caco-2TC7 cells are a highly dierentiated subclone of the standard Caco-2 cell line (Chantret et al., 1994) . In these cells again, the endogenous levels of Cdx-1 and Cdx-2 mRNAs were respectively increased and decreased by oncogenic ras activation ( Figure 1a ). To examine whether these eects were associated with changes in the transcriptional activity of the Cdx-1 and Cdx-2 promoters, we have constructed the reporter pCdx1-4Luc and pCdx2-1Luc plasmids containing respectively a 4-kb fragment of the murine Cdx-1 promoter, and a 1-kb fragment of the murine Cdx-2 promoter upstream of the luciferase gene. These plasmids were introduced into control Caco-2H and into constitutively ras-activated Caco-2T/ MT cells. Luciferase activity triggered by the Cdx-1 promoter largely increased in the ras-activated cell lines (Figure 1b) , whereas luciferase activity under the control the Cdx-2 promoter decreased by 60% (Figure 1c ). Consistent with these data, the introduction of activated Val12 Ha-ras in Caco-2TC7 cells by transient co-transfection of pHO6T1 and pCdx1-4Luc stimulated luciferase activity (Figure 1b) , whereas cotransfection of pHO6T1 and pCdx2-1Luc caused a 90% decline of luciferase activity (Figure 1c) . In another human adenocarcinoma cell line, the HT-29 cells, transient expression of oncogenic ras also decreased by 70% the Cdx-2 promoter activity, indicating that this eect is not restricted to Caco-2 cells (Figure 1c ). Taken together, these results demonstrate that oncogenic activation of ras in human colonic cancer cells results in the downregulation of the tumour-suppressor Cdx-2 homeobox gene, and in the upregulation of the related Cdx-1 gene that displays oncogenic potential.
Distinct cytoplasmic pathways mediate the ras eects on Cdx-1 and Cdx-2
We next examined the cytoplasmic signalling pathway(s) that mediate the ras eects on Cdx-1 and Cdx-2. The ras-activated Caco-2T/MT cell lines display MAP kinase activation (Baron- Delage et al., 1994) , as well as constitutive PKC activation and PKCa overexpression (Delage et al., 1993) . To test the involvement of these signalling pathways in the ras-dependent alterations of Cdx-1 and Cdx-2 expression, rasactivated Caco-2M/MT cells were treated for longterm with PD 98059, an upstream inhibitor of MAP kinase, or with PMA to downregulate PKC activity. Figure 2a shows that MAP kinase inhibition by PD 98059 treatment lowered the level of Cdx-1 mRNA without eect on Cdx-2. Inversely, PKC depletion by PMA treatment restored Cdx-2 mRNA expression without change in Cdx-1 transcripts (Figure 2a ). The participation of PKCa in the ras-dependent decline of Cdx-2 was con®rmed by transient transfection of Caco-2TC7 cells with pcDNA-PKCa encoding human PKCa; in these cells, the level of Cdx-2 mRNA decreased (Figure 2b ), like in the pHO6T1-transfected cells ( Figure 1a) ; interestingly, this treatment was without eect on the Cdx-1 mRNA. Moreover, cotransfection of the pCdx2-1Luc reporter with pcDNAPKCa reduced luciferase activity triggered by the Cdx-2 promoter (Figure 2b ), although to a lesser extent compared to Caco-2 cells transiently transfected with pHO6T1 ( Figure 1c ). From these results, we conclude that oncogenic ras uses distinct signalling pathways to alter the expression of the Cdx-1 and Cdx-2 homeobox genes, and that the stimulatory eect of ras on Cdx-1 is MEK1/MAPK-dependent, whereas the inhibitory eect on Cdx-2 is PKC-dependent. Figure 4a , the level of Cdx-2 mRNA increased by Jun expression, it reached a level equivalent to that obtained in control cells by coexpression of Jun and Fos, and it was reduced by Fos alone. These results were corroborated using the same plasmids in Caco-2TC7 cells co-transfected with the pCdx2-1Luc reporter. Indeed, luciferase activity triggered by the Cdx-2 promoter increased sixfold by Jun, co-expression of Fos with Jun reversed the Jun eect, and Fos alone blocked the transcriptional activity of this promoter (Figure 4b ). JunB and JunD also stimulated the activity of the Cdx-2 promoter, and their eects were blocked by Fos (Figure 4b) . Evidence for the implication of the Cdx2-AP1 binding site in the Jun stimulation of the Cdx-2 promoter was provided by site-directed mutagenesis, because changing the TGTGTCAT sequence into TGTGTTGT prevented the Jun-dependent increase of luciferase activity (not shown). Taken together, these results indicate that the Jun/Fos balance controls Cdx-2 expression, and that Fos is a negative regulator of the Jun-mediated stimulation of the Cdx-2 promoter activity.
Downregulation of

Change in the Jun/Fos balance by oncogenic ras and by PKCa
In this study, we have shown on the one hand that oncogenic ras downregulates Cdx-2 via a PKCdependent pathway and on the other hand that the transcriptional activity of the Cdx-2 promoter is related to the Jun/Fos balance. To investigate a relationship between the PKC-mediated decrease of Cdx-2 expression in ras-activated cells and the opposite eects of Jun/Fos on the Cdx-2 promoter, the endogenous levels of c-jun and c-fos mRNAs were analysed in control Caco-2H and in constitutively ras-activated Caco-2T/ MT cell lines, in ras-activated cell lines after PKC depletion by long-term PMA treatment, and in Caco-2TC7 cells in which PKCa activity was stimulated by transient transfection with pcDNA-PKCa. Comparison of the c-jun and c-fos transcripts in control Caco-2H and in ras-activated Caco-2T/MT cell lines indicated a decrease in c-jun mRNA by oncogenic ras activation (Figure 5d ). Moreover, PKC depletion in ras-activated Caco-2T/MT cells by long-term PMA treatment upregulated c-jun mRNA (Figure 5e ). We conclude from these experiments that the decrease in Cdx-2 expression by constitutive activation of ras correlates with a PKC-dependent depletion of Jun, favouring the negative eect exerted by Fos on the activity of the Cdx-2 promoter.
Discussion
Constitutive activation of p21ras is widespread in colorectal cancers (Fearon and Vogelstein, 1990; Ilyas and Tomlinson, 1996) . In this study, we demonstrate that oncogenic ras activation in both Caco-2 and HT-29 colonic cells results in opposite eects on two caudal-related homeobox genes that play crucial roles during the constant renewal (proliferation and dierentiation) of the intestinal epithelium: it downregulates Cdx-2, a tumour-suppressor gene (Chawengsaksophak et al., 1997), and it upregulates Cdx-1 that displays oncogenic potential (Maulbecker and Gruss, 1993) . The ras eects on Cdx-1 and Cdx-2 use distinct signalling pathways dependent respectively on MEK1-MAP kinase and on PKC activation. In addition, we show that the decrease in Cdx-2 expression triggered by oncogenic ras and mediated by PKC activation involves a decline of c-jun expression, thus modifying the Jun/Fos balance in favour of a negative eect exerted by c-Fos on the Cdx-2 promoter.
The ras-dependent decrease in Cdx-2 expression reported here in vitro in human colonic Caco-2 and HT-29 cells is fully consistent with the decline of expression of this tumour-suppressor gene that correlates to the pathological grade in human colorectal cancers and in chemically-induced colonic tumours in the rat (Ee et al., 1995; Mallo et al., 1997) . Our results therefore suggest that in vivo, like in cultured cells, Cdx-2 is a target of oncogenic ras. This hypothesis is also consistent with the loss of Cdx-2 expression reported in the multiple colonic adenomas occurring in heterozygous Cdx-2 knock-out mice, despite the maintenance of active expression of the single resident wild type gene in epithelial cells adjacent to the tumours (Chawengsaksophak et al., 1997) . The decline in Cdx-2 mRNA expression by oncogenic ras is compatible with the fact that sucrase-isomaltase expression, a typical target of the CDX-2 protein, is turned o in ras-activated Caco2T/ MT cells (Baron- Delage et al., 1996) . Further studies are needed to investigate whether oncogenic ras also has an eect on the proper activity of the CDX-2 protein through posttranscriptional modi®cations, in addition to the eect reported here on Cdx-2 gene expression. Taken together, our data provide evidence that, besides the well-known structural genetic alterations that prevent the expression of colonic tumour-suppressor genes like APC or p53, the loss of expression of a tumour-suppressor gene, i.e. Cdx-2, can also result from an alteration of regulatory pathways disturbed by oncogenic processes. Although the way by which Cdx-2 exerts its tumour-suppressor action is far from being elucidated, it is worth nothing that this homeobox gene stimulates the expression of APC and E-cadherin, which are themselves identi®ed as tumour-suppressors .
The function and the role of Cdx-1 in intestinal development and tumorigenesis are not as clear as for Cdx-2. Although Cdx-1 expression drops in some colonic cancers, a tumour-suppressor role seems to be ruled out because no colonic tumour has been reported in homozygous Cdx-1 knock out mice (Subramaniam et al., 1995) . Instead, (i) ectopic Cdx-1 expression accompanies the development of intestinal metaplasia in oesophagus or gastric cancers (Silberg et al., 1997) ; (ii) Cdx-1 overexpression stimulates cell tumorigenicity (Maulbecker and Gruss, 1993) ; and (iii) inhibition of Cdx-1 expression by antisense RNA in Caco-2 cells results in reduced cell proliferation . These observations rather suggest that Cdx-1 is a homeobox gene with oncogenic potential. The stimulation of Cdx-1 reported in this study by oncogenic ras in colonic Caco-2 cells is consistent with the onset of expression found in metaplasic areas of oesophagus and gastric cancers, since oncogenic ras activation is often associated with well dierentiated tumours of the upper digestive tract (Peddanna et al., 1995) . Thus, during early events in the progression of normal colonic epithelium to adenoma, oncogenic ras activation would stimulate Cdx-1; additional genetic alterations may subsequently downregulate this gene during further progression to adenocarcinoma and distant metastasis, as observed by Silberg et al. (1997) , Mallo et al. (1997) and Vider et al. (1997) . This hypothesis is supported by the fact that the decrease of Cdx-1 in colonic cancers was found not to be related to the pathological grade (Silberg et al., 1997) , in contrast to what was reported for Cdx-2 (Ee et al., 1995) .
We show here that the ras-dependent PKCa activation reduces the level of c-jun mRNA, and thus modi®es the Jun/Fos balance in favour of a negative eect of c-Fos that counters the stimulatory eect exerted by c-Jun on the Cdx2-AP1 cis-element. Opposing actions of Jun and Fos have already been reported for the phosphoenolpyruvate carboxykinase gene promoter (Gurney et al., 1992 ). Yet, one can mention that in co-transfection experiments, the negative eect of PKCa on the activity of the Cdx-2 promoter is lower than the action exerted by Ha-ras. It is therefore possible that, beside the PKC-mediated eect, ras additionally alters Cdx-2 gene transcription through PKC-independent pathway(s). In this case, we can exclude the P13K (Phosphatidyl-Inositol-3 kinase) and NF-kB pathways, because the treatment of Caco-2T/MT/MT cells by LY294002 to inhibit P13K activity or by TNFa to restore the NF-kB activity altered by Ha-ras (Cadoret et al., 1997) , are ineective on the expression of Cdx-2 downregulated by oncogenic ras; we also rule out the JNK/SAPK pathway (Jun Nterminal kinase/Stress-Activated-Protein kinase) because JNK activity is unchanged in ras-activated Caco-2T/MT cells compared to control cells (unpublished results) .
The fact that the Cdx-2 tumour-suppressor gene is a target of intracellular signalling pathways and of the Jun/Fos balance has several implications. First, increased Fos has been reported in aberrant crypt foci, the earliest detectable lesions in colon cancers (Stopera et al., 1992) , suggesting that Cdx-2 expression may already be aected during early stages of tumorigenesis. Second, PKC activity and the Jun/Fos balance are modulated by dietary components having either a promoting eect or a protective role on colonic tumours (Davidson et al., 1995; Velazquez et al., 1996) . Hence, it is conceivable that the endogenous level of Cdx-2 expression may vary with dietary habits, thus modifying the individual risk of progression of colorectal tumours. The last aspect concerns the possible link between Cdx-2 and APC, a major gene altered in many colonic cancers: indeed, Cdx-2 expression is turned o in the colonic tumours developed by min mice that display a mutated form of the APC gene (Chawengsaksophak et al., 1997) , opening the way to investigate whether Cdx-2 is a target of APC signalling.
Material and methods
Plasmids
The reporter pCdx1-4Luc and pCdx2-1Luc plasmids containing promoter fragments of the murine Cdx-1 and Cdx-2 genes were constructed using pGL3-Basic (Promega), according to standard procedures (Sambrook et al., 1989) . The ScaI ± SphI fragment of pCdx1 ± 34 containing the 5' region of the Cdx-1 gene was fused with the 1.7-kb SphI ± ScaI fragment of pUC18; the resulting 4-kb HindIII fragment covering the Cdx-1 promoter was inserted in the corresponding site of pGL3-Basic to give pCdx1-4Luc. The 1-kb insert of pCdx2-1Luc was obtained by PCR on murine genomic DNA using the primers Cdx2P a/b: d CCAGCCATCCACTAATTACT / dGCTGTCTGGGGA-CAAACGTT (James et al., 1994) . Plasmid pHO6T1 encodes the human mutated (Val 12) Ha-ras oncoprotein (Spandidos and Wilkie, 1984) , pcDNA-PKCa encodes human pKCa (Finkenzeller et al., 1992) , pSV-c-jun and pBK28-c-fos code for the murine c-Jun and human c-Fos proteins (Sassone-Corsi et al., 1988; Van Beveren et al., 1983) ; pCR3 was from Invitrogen.
Cells and transfections
Cells were grown under standard conditions : they were seeded at low density (1.2 cells610 4 per cm 2 ) and passaged every 7 days; cultures were performed in 5% CO 2 /95% air atmosphere using DME (Gibco BRL) containing 20% fetal calf serum 1% non essential amino acids, 1% penicillin, 1% streptomycin, 0.1% gentamycin. The Caco-2TC7 cells (Chantret et al., 1994) correspond to a highly dierentiated subclone of the human colonic adenocarcinoma Caco-2 cell line that exhibits spontaneous enterocytic-like dierentiation in culture (Pinto et al., 1983) and a very low tumorigenic potential (Rousset et al., 1980) . Cells of the human colonic carcinoma HT-29 cell line are undierentiated in culture (Pinto et al., 1982) . Both Caco-2 and HT-29 cells have normal ras proto-oncogene. The control Caco-2H and the ras-activated Caco-2T and Caco-2MT cell lines were obtained by stable transfection with the pHO6 vector, with pHO6T1 encoding the mutated (Val12) Ha-ras oncoprotein (Spandidos and Wilkie, 1984) , and with pHO6MT1 encoding the polyoma middle T antigen (Spandidos and Riggio 1986). They have already been characterized as regards the eects of constitutive ras activation on cell proliferation and dierentiation, tumorigenicity, PKC and MAP kinase activities Delage et al., 1993; Baron-Delage et al., 1994 . Cells were treated for 17 h with 100 mM PD 98059 or for 24 h with 2.5 mM PMA, as previously described (Delage et al., 1993) .
For transient transfection experiments, cells were trypsinized and seeded at 0.12610 6 cells per 1.75 cm 2 well. The next day, they were placed in fresh culture medium 3 h before transfection. Then, 2 mg DNA in 100 ml NaCl 150 mM and 6 ml Exgen 500 (Euromedex) were added to the culture medium, cells were centrifuged at 400 g for 5 min as recommended by the supplier and incubated at 378C for 6 h before the solution was replaced by fresh medium. Luciferase activity was measured after 48 h with the Luciferase Assay System (Promega) using a Lumistar luminometer (BMG LabTechnologies). Co-transfection with pCMV-b Gal (Clontech) and measurement of b-galactosidase activity with ONPG (Sambrook et al., 1989) were used to standardize the results.
mRNA analysis by RT ± PCR
Semi-quantitative RT ± PCR was performed as described previously Lorentz et al., 1997) for increasing number of cycles (24 ± 40 cycles). The speci®c primers used for the Cdx-1, Cdx-2, c-jun and c-fos mRNAs were respectively cdx1 a/b: dGCGCCAAGGCG-GACG CCCTACGAAT / d TGTTTACTTTGCGCTCCTT-GGCCCG , cdx2 b/c: dCCCA-GCGGCCAGCGGCGAAACCTGT / dTATTTGTCTTTT-GTCCTGGTTTTCA , c-jun a/b: dGAA TTGTC AAAGAGAAGATTCCAAA / dGAGTTG-AAAGAGTTAAGAATGCTCG and c-fos a/b: dAAACA-CATCTTCCCTAGAGGGTTCC / dACACA CTATTGCC-AGGAACACAGTA. Results were compared to those obtained with the 36B4 ribosomal protein-encoding mRNA, using the primers PG193/194: dATGTGAA-GTCACTGTGCCAG / dG TGTAATCCGTCTCCACAGA . Quantitative analysis of the c-jun mRNA by competitive RT ± PCR was performed using the c-jun a/b primers; the PCR reaction contained a constant amount of single stranded oligo-dT-primed cDNA and serial dilutions of competitor DNA synthesised with the primers c-jun-b and c-jun-comp (dGAAAGAGTTAAGA-ATGCTCGGGGTTGCAGTGGAGAGGGACA) (FoÈ ster, 1994) . PCR fragments were analysed using an Imaging Densitometer (Bio-Rad Laboratories).
Electromobility shift assays (EMSA)
EMSA was performed as previously described (Cadoret et al., 1997) , with the labelled double-stranded Cdx2-AP1 oligonucleotide (d CGA TTGGTGTCTGTGTCAT-TAC TA ATAGA / dAGACTCTAT TAGTA ATGACACA-GACACCA). Competition with DNA used a 30-fold excess of unlabelled oligonucleotide; the DNA competitors were Cdx2-AP1, Std-AP1 (dCGCTTGATGAGTCAGCCG-GAA/dTTCCG-GCTGACTCATCAAGCG) containing a consensus AP-1 binding site, or OCT-1 (dTGTCGAATG-CAAATCACTAGAA/dTTCTAGTGATTTGCATTCGA-CA) containing an OCT-1 site. Competition with monoclonal antibodies (1 mg antibody for 1 h at 48C) was carried out with antiJun (Oncogene Science) or antiFos/ FosB/Fra1/Fra2 antibody (Santa Cruz Biotechnology Inc.).
